Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LELAND N ALLEN

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1245258573
CMS profile
55913
Location
BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$368.99

13 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $212.01 11
Education $156.98 2

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LELAND N ALLEN

NPI 1245258573 · CMS profile ID 55913

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1245258573?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LELAND N ALLEN, NPI 1245258573, CMS profile ID 55913. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1245258573?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). LELAND N ALLEN, NPI 1245258573, CMS profile ID 55913. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1245258573?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
LELAND N ALLEN, NPI 1245258573, CMS profile ID 55913, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1245258573?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

13 matching records · $368.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 13 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–13 of 13.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $15.1312/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141625745 CMS
La Jolla Pharmaceutical Company $15.7711/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154246916 CMS
Paratek Pharmaceuticals, Inc. $15.2210/02/2024 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 1113890448 CMS
La Jolla Pharmaceutical Company $25.8309/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154246914 CMS
Melinta Therapeutics, LLC $21.5108/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140483190 CMS
La Jolla Pharmaceutical Company $14.9208/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154246912 CMS
La Jolla Pharmaceutical Company $23.1006/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154246910 CMS
Novo Nordisk Inc $15.9506/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097803004 CMS
La Jolla Pharmaceutical Company $15.3504/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154246908 CMS
AstraZeneca Pharmaceuticals LP $32.1801/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105899440 CMS
Astellas Pharma US Inc $17.0501/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139290480 CMS
Astellas Pharma US Inc $76.9901/18/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139388352 CMS
Astellas Pharma US Inc $79.9901/18/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139388354 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,146.19 68
PY2020 $344.62 27
PY2021 $468.66 29
PY2022 $127.11 7
PY2023 $45.03 3
PY2024 $368.99 13
PY2025 $356.74 16

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $394,977.43 20
PY2023 Principal investigator $532,033.34 44
PY2022 Principal investigator $2,884,761.18 187
PY2021 Principal investigator $4,662,082.09 207

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

187 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $5,850.84 12/28/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949772637
Principal investigator 1 ModernaTX, Inc. $931.50 12/23/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963651823
Principal investigator 1 ModernaTX, Inc. $1,944.00 12/23/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963651827
Principal investigator 1 PFIZER INC. $4,520.88 12/21/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949772903
Principal investigator 1 PFIZER INC. $7,376.65 12/17/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949772905
Principal investigator 1 PFIZER INC. $25,548.74 12/16/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949772673
Principal investigator 1 PFIZER INC. $77,937.07 12/10/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949772635
Principal investigator 1 ModernaTX, Inc. $2,880.00 12/09/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963651849
Principal investigator 1 PFIZER INC. $50,749.72 12/03/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949772633
Principal investigator 1 PFIZER INC. $772.20 11/30/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949781879
Principal investigator 1 PFIZER INC. $32,624.82 11/23/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949781883
Principal investigator 1 PFIZER INC. $37.26 11/21/2022 Covered Recipient Teaching Hospital
St Vincents Birmingham
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759657
Principal investigator 1 PFIZER INC. $779.70 11/16/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949782475
Principal investigator 1 PFIZER INC. $2,815.20 11/09/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949781921
Principal investigator 1 PFIZER INC. $37.26 11/08/2022 Covered Recipient Teaching Hospital
St Vincents Birmingham
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759065
Principal investigator 1 PFIZER INC. $37.26 11/07/2022 Covered Recipient Teaching Hospital
St Vincents Birmingham
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759063
Principal investigator 1 ModernaTX, Inc. $12,069.00 11/02/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963255025
Principal investigator 1 ModernaTX, Inc. $12,312.00 11/02/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963255037
Principal investigator 1 ModernaTX, Inc. $8,930.25 11/02/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963255049
Principal investigator 1 ModernaTX, Inc. $7,722.00 11/02/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963255055
Principal investigator 1 ModernaTX, Inc. $7,776.00 11/02/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963255065
Principal investigator 1 ModernaTX, Inc. $7,398.00 11/02/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963255077
Principal investigator 1 PFIZER INC. $25,182.44 11/02/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949781881
Principal investigator 1 PFIZER INC. $16,820.00 10/28/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949788227
Principal investigator 1 PFIZER INC. $11,026.20 10/28/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949789067
Principal investigator 1 PFIZER INC. $6,462.54 10/27/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949789099
Principal investigator 1 Gilead Sciences, Inc. $9,558.00 10/24/2022 Non-covered Recipient Entity
ST VINCENTS HEALTH SYSTEM
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are Hospitalized for COVID-19 No dispute reported 06/30/2026 920358925
Principal investigator 1 Gilead Sciences, Inc. $9,758.00 10/24/2022 Non-covered Recipient Entity
ST VINCENTS HEALTH SYSTEM
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are Hospitalized for COVID-19 No dispute reported 06/30/2026 920358927
Principal investigator 1 ModernaTX, Inc. $7,057.10 10/14/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254939
Principal investigator 1 PFIZER INC. $2,243.88 10/14/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949788435
Principal investigator 1 PFIZER INC. $55.89 10/13/2022 Covered Recipient Teaching Hospital
St Vincents Birmingham
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759145
Principal investigator 1 ModernaTX, Inc. $720.00 10/07/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254957
Principal investigator 1 ModernaTX, Inc. $1,200.00 10/07/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254973
Principal investigator 1 ModernaTX, Inc. $600.00 10/07/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254979
Principal investigator 1 ModernaTX, Inc. $150.00 10/07/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254991
Principal investigator 1 ModernaTX, Inc. $480.00 10/07/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254997
Principal investigator 1 ModernaTX, Inc. $785,133.98 10/05/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254921
Principal investigator 1 ModernaTX, Inc. $350.00 10/05/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254951
Principal investigator 1 ModernaTX, Inc. $575.00 10/05/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254967
Principal investigator 1 PFIZER INC. $747.96 09/30/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949788439
Principal investigator 1 PFIZER INC. $16,767.00 09/24/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949788437
Principal investigator 1 ModernaTX, Inc. $455.30 09/07/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252451
Principal investigator 1 ModernaTX, Inc. $5,235.92 08/24/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253411
Principal investigator 1 ModernaTX, Inc. $7,967.70 08/22/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253619
Principal investigator 1 ModernaTX, Inc. $4,782.33 08/17/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253371
Principal investigator 1 PFIZER INC. $26,247.60 08/16/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949802427
Principal investigator 1 ModernaTX, Inc. $7,830.00 08/12/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253601
Principal investigator 1 ModernaTX, Inc. $958.52 08/10/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252947
Principal investigator 1 ModernaTX, Inc. $10,955.25 08/10/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253743
Principal investigator 1 PFIZER INC. $10,060.20 07/29/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949806825
Principal investigator 1 ModernaTX, Inc. $1,680.08 07/27/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253059
Principal investigator 1 ModernaTX, Inc. $1,680.08 07/27/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253065
Principal investigator 1 ModernaTX, Inc. $1,680.08 07/27/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253069
Principal investigator 1 ModernaTX, Inc. $2,520.11 07/27/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253145
Principal investigator 1 ModernaTX, Inc. $5,040.23 07/27/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253399
Principal investigator 1 ModernaTX, Inc. $7,560.34 07/27/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253583
Principal investigator 1 ModernaTX, Inc. $11,760.53 07/27/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253785
Principal investigator 1 ModernaTX, Inc. $12,600.56 07/27/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253819
Principal investigator 1 ModernaTX, Inc. $15,938.29 07/27/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253931
Principal investigator 1 ModernaTX, Inc. $18,128.14 07/27/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253983
Principal investigator 1 ModernaTX, Inc. $538.65 07/20/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252837
Principal investigator 1 ModernaTX, Inc. $7,776.00 07/20/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253589
Principal investigator 1 ModernaTX, Inc. $12,757.50 07/20/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253831
Principal investigator 1 ModernaTX, Inc. $2,968.65 07/13/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253216
Principal investigator 1 ModernaTX, Inc. $12,089.25 07/08/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254423
Principal investigator 1 ModernaTX, Inc. $22,815.00 06/29/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254123
Principal investigator 1 PFIZER INC. $12,278.23 06/29/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949813667
Principal investigator 1 ModernaTX, Inc. $227.65 06/22/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252403
Principal investigator 1 ModernaTX, Inc. $7,992.00 06/22/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253637
Principal investigator 1 ModernaTX, Inc. $7,830.00 06/17/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253595
Principal investigator 1 ModernaTX, Inc. $11,137.50 06/17/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253749
Principal investigator 1 PFIZER INC. $15,913.60 06/15/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949813665
Principal investigator 1 ModernaTX, Inc. $1,359.45 06/08/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253023
Principal investigator 1 ModernaTX, Inc. $6,797.25 06/08/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253529
Principal investigator 1 ModernaTX, Inc. $15,000.78 06/08/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253889
Principal investigator 1 ModernaTX, Inc. $16,390.69 06/08/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253949
Principal investigator 1 ModernaTX, Inc. $227.65 06/03/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252399
Principal investigator 1 ModernaTX, Inc. $682.95 06/03/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252847
Principal investigator 1 ModernaTX, Inc. $1,359.45 06/03/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253011
Principal investigator 1 ModernaTX, Inc. $1,359.45 06/03/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253017
Principal investigator 1 ModernaTX, Inc. $2,718.90 06/03/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253179
Principal investigator 1 ModernaTX, Inc. $2,718.90 06/03/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253185
Principal investigator 1 ModernaTX, Inc. $3,656.42 06/03/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253275
Principal investigator 1 ModernaTX, Inc. $4,078.35 06/03/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253305
Principal investigator 1 ModernaTX, Inc. $5,437.80 06/03/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253435
Principal investigator 1 ModernaTX, Inc. $5,906.56 06/03/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253475
Principal investigator 1 ModernaTX, Inc. $9,790.62 06/03/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253721
Principal investigator 1 ModernaTX, Inc. $10,922.43 06/03/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253739
Principal investigator 1 ModernaTX, Inc. $11,344.36 06/03/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253755
Principal investigator 1 ModernaTX, Inc. $16,313.40 06/03/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253943
Principal investigator 1 ModernaTX, Inc. $17,649.78 06/03/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253971
Principal investigator 1 ModernaTX, Inc. $20,854.45 06/03/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254073
Principal investigator 1 PFIZER INC. $6,036.12 05/27/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949749059
Principal investigator 1 ModernaTX, Inc. $173.14 05/20/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252367
Principal investigator 1 ModernaTX, Inc. $173.14 05/20/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252371
Principal investigator 1 ModernaTX, Inc. $346.28 05/20/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252431
Principal investigator 1 ModernaTX, Inc. $840.04 05/20/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252887
Principal investigator 1 ModernaTX, Inc. $1,680.08 05/20/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253053
Principal investigator 1 ModernaTX, Inc. $5,040.23 05/20/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253395
Principal investigator 1 ModernaTX, Inc. $6,232.95 05/20/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253507
Principal investigator 1 ModernaTX, Inc. $7,884.00 05/20/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253607
Principal investigator 1 ModernaTX, Inc. $11,745.00 05/20/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253773
Principal investigator 1 ModernaTX, Inc. $14,280.64 05/20/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253873
Principal investigator 1 ModernaTX, Inc. $16,800.75 05/20/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253965
Principal investigator 1 ModernaTX, Inc. $21,000.94 05/20/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254083
Principal investigator 1 PFIZER INC. $27,693.42 05/14/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949749065
Principal investigator 1 ModernaTX, Inc. $3,187.66 05/06/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253221
Principal investigator 1 ModernaTX, Inc. $3,187.66 05/06/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253227
Principal investigator 1 ModernaTX, Inc. $8,203.53 05/06/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253673
Principal investigator 1 ModernaTX, Inc. $13,289.28 05/06/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253843
Principal investigator 1 ModernaTX, Inc. $23,955.21 05/06/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254153
Principal investigator 1 PFIZER INC. $13,020.30 04/29/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949822733
Principal investigator 1 PFIZER INC. $18,200.82 04/14/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949822951
Principal investigator 1 ModernaTX, Inc. $5,437.80 04/01/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253429
Principal investigator 1 ModernaTX, Inc. $7,335.90 04/01/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253554
Principal investigator 1 ModernaTX, Inc. $8,156.70 04/01/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253643
Principal investigator 1 ModernaTX, Inc. $29,603.64 04/01/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254217
Principal investigator 1 ModernaTX, Inc. $56,736.96 04/01/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254329
Principal investigator 1 PFIZER INC. $12,094.56 04/01/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949822735
Principal investigator 1 ModernaTX, Inc. $5,437.80 03/30/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253423
Principal investigator 1 PFIZER INC. $3,223.68 03/16/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949826077
Principal investigator 1 ModernaTX, Inc. $4,415.86 03/09/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253341
Principal investigator 1 ModernaTX, Inc. $7,992.00 03/09/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253631
Principal investigator 1 ModernaTX, Inc. $13,284.00 03/09/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253837
Principal investigator 1 ModernaTX, Inc. $51,278.49 03/09/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254299
Principal investigator 1 ModernaTX, Inc. $84.38 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252299
Principal investigator 1 ModernaTX, Inc. $153.57 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252305
Principal investigator 1 ModernaTX, Inc. $172.13 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252311
Principal investigator 1 ModernaTX, Inc. $172.13 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252317
Principal investigator 1 ModernaTX, Inc. $384.75 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252435
Principal investigator 1 ModernaTX, Inc. $2,463.75 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253121
Principal investigator 1 ModernaTX, Inc. $2,474.55 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253127
Principal investigator 1 ModernaTX, Inc. $2,632.56 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253161
Principal investigator 1 ModernaTX, Inc. $4,452.40 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253347
Principal investigator 1 ModernaTX, Inc. $4,637.96 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253359
Principal investigator 1 ModernaTX, Inc. $4,718.93 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253365
Principal investigator 1 ModernaTX, Inc. $6,816.52 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253541
Principal investigator 1 ModernaTX, Inc. $7,487.79 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253565
Principal investigator 1 ModernaTX, Inc. $7,958.32 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253613
Principal investigator 1 ModernaTX, Inc. $8,890.54 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253691
Principal investigator 1 ModernaTX, Inc. $11,704.86 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253767
Principal investigator 1 ModernaTX, Inc. $13,640.07 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253849
Principal investigator 1 ModernaTX, Inc. $28,319.03 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254189
Principal investigator 1 ModernaTX, Inc. $28,886.69 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254199
Principal investigator 1 ModernaTX, Inc. $30,731.77 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254223
Principal investigator 1 ModernaTX, Inc. $31,981.86 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254235
Principal investigator 1 ModernaTX, Inc. $32,373.73 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254241
Principal investigator 1 ModernaTX, Inc. $53,044.95 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254305
Principal investigator 1 ModernaTX, Inc. $57,117.25 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254335
Principal investigator 1 ModernaTX, Inc. $70,206.61 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254365
Principal investigator 1 ModernaTX, Inc. $85,361.11 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254389
Principal investigator 1 ModernaTX, Inc. $92,396.87 03/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254405
Principal investigator 1 PFIZER INC. $22,400.16 02/25/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949829781
Principal investigator 1 ModernaTX, Inc. $538.65 02/23/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252827
Principal investigator 1 ModernaTX, Inc. $1,289.56 02/23/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252999
Principal investigator 1 ModernaTX, Inc. $1,400.00 02/23/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253041
Principal investigator 1 ModernaTX, Inc. $3,656.42 02/23/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253257
Principal investigator 1 ModernaTX, Inc. $3,884.07 02/23/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253289
Principal investigator 1 ModernaTX, Inc. $6,774.18 02/23/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253523
Principal investigator 1 ModernaTX, Inc. $11,507.90 02/23/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253761
Principal investigator 1 ModernaTX, Inc. $20,730.05 02/23/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963254067
Principal investigator 1 ModernaTX, Inc. $346.28 02/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252409
Principal investigator 1 ModernaTX, Inc. $692.55 02/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252853
Principal investigator 1 ModernaTX, Inc. $840.04 02/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252877
Principal investigator 1 ModernaTX, Inc. $1,038.83 02/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252957
Principal investigator 1 ModernaTX, Inc. $4,567.01 02/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253353
Principal investigator 1 ModernaTX, Inc. $16,715.72 02/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253959
Principal investigator 1 ModernaTX, Inc. $18,480.83 02/04/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253995
Principal investigator 1 PFIZER INC. $84,720.96 02/04/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949829793
Principal investigator 1 ModernaTX, Inc. $173.14 02/02/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252333
Principal investigator 1 ModernaTX, Inc. $538.65 02/02/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252833
Principal investigator 1 ModernaTX, Inc. $865.69 02/02/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252911
Principal investigator 1 ModernaTX, Inc. $1,038.83 02/02/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252963
Principal investigator 1 ModernaTX, Inc. $1,211.96 02/02/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963252981
Principal investigator 1 ModernaTX, Inc. $1,304.30 02/02/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253005
Principal investigator 1 ModernaTX, Inc. $1,731.38 02/02/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253081
Principal investigator 1 ModernaTX, Inc. $1,828.21 02/02/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253087
Principal investigator 1 ModernaTX, Inc. $3,656.42 02/02/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253263
Principal investigator 1 ModernaTX, Inc. $3,656.42 02/02/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253269
Principal investigator 1 ModernaTX, Inc. $6,521.51 02/02/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253511
Principal investigator 1 ModernaTX, Inc. $7,992.00 02/02/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253625
Principal investigator 1 ModernaTX, Inc. $8,602.39 02/02/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253685
Principal investigator 1 ModernaTX, Inc. $11,760.53 02/02/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253779
Principal investigator 1 ModernaTX, Inc. $11,826.00 02/02/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253791
Principal investigator 1 ModernaTX, Inc. $12,065.37 02/02/2022 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 963253797
Principal investigator 1 Gilead Sciences, Inc. $214.00 01/10/2022 Non-covered Recipient Entity
ST VINCENTS HEALTH SYSTEM
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are Hospitalized for COVID-19 No dispute reported 06/30/2026 920358923
Principal investigator 1 PFIZER INC. $25,044.24 01/08/2022 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949831405